Human skin not only serves as an important barrier against the penetration of exogenous substances into the body, but also provides a potential avenue for the transport of functional active drugs/reagents/ingredients into the skin (topical delivery) and/or the body (transdermal delivery). In the past three decades, research and development in human skin equivalents have advanced in parallel with those in tissue engineering and regenerative medicine. The human skin equivalents are used commercially as clinical skin substitutes and as models for permeation and toxicity screening. Several academic laboratories have developed their own human skin equivalent models and applied these models for studying skin permeation, corrosivity and irritation, compound toxicity, biochemistry, metabolism and cellular pharmacology. Various aspects of the state of the art of human skin equivalents are reviewed and discussed.
References
[1]
Holbrook, K.A.; Wolff, K. The Structure and Development of Skin. In Dermatology in General Medicine, 6th; Fitzpatrick, T.B., Eisen, A.Z., Wolff, K., Freedberg, I.M., Austen, K.F., Eds.; McGraw-Hill: New York, NY, USA, 1993.
[2]
Scheuplein, R.J.; Blank, I.H. Permeability of the skin. Physiol. Rev. 1971, 51, 702–747.
[3]
Briggaman, R.A.; Wheeler, C.E., Jr. The epidermal-dermal junction. J. Invest. Dermatol. 1975, 65, 71–84.
[4]
Parenteau, N.L.; Hardin-Young, J.; Ross, R.N. Skin. In Principles of Tissue Engineering, 2nd; Lanza, R.P., Langer, R., Vacanti, J.P., Eds.; Academic Press: San Diego, CA, USA, 2000; pp. 879–890.
[5]
Hadgraft, J.; Guy, R.H. Feasibility Assessment in Topical and Transdermal Delivery: Mathematical Models and in Vitro Studies. In Transdermal Drug Delivery, 2nd; Guy, R.H., Hadgraft, J., Eds.; Marcel Dekker, Inc.: New York, NY, USA, 2003. Chapter 1.
[6]
Zhang, Q.; Grice, J.E.; Li, P.; Jepps, O.G.; Wang, G.-J.; Roberts, M.S. Skin solubility determines maximum transepidermal flux for similar size molecules. Pharm. Res. 2009, 26, 1974–1985, doi:10.1007/s11095-009-9912-4.
[7]
Vacanti, J.P.; Vacanti, C.A. The History and Scope of Tissue Engineering. In Principles of Tissue Engineering, 2nd; Lanza, R.P., Langer, R., Vacanti, J.P., Eds.; Academic Press: San Diego, CA, USA, 2000; pp. 3–7.
Rheinwald, J.G.; Green, H. Serial cultivation of strains of human epidermal keratinocytes: The Formation of keratinizing colonies from single cells. Cell 1975, 6, 331–337, doi:10.1016/S0092-8674(75)80001-8.
[10]
Rheinwald, J.G.; Green, H. Epidermal growth factor and the multiplication of cultured human epidermal keratinocytes. Nature 1977, 264, 421–424, doi:10.1038/265421a0.
[11]
Green, H.; Kehinde, O.; Thomas, J. Growth of cultured human epidermal cells into multiple epithelia suitable for grafting. Proc. Natl. Acad. Sci. USA 1979, 76, 5665–5668, doi:10.1073/pnas.76.11.5665.
[12]
Bell, E.; Ehrlich, H.P.; Buttle, D.J.; Nakatsuji, T. Living tissue formed in vitro and accepted as skin-equivalent tissue of full thickness. Science 1981, 211, 1052–1054.
[13]
Deuel, T.F.; Kawahara, R.S.; Mustoe, T.A.; Pierce, A.F. Growth factors and wound healing: Platelet-derived growth factor as a model cytokine. Annu. Rev. Med. 1991, 42, 567–584, doi:10.1146/annurev.me.42.020191.003031.
[14]
Freed, L.E.; Hollander, A.P.; Martin, I.; Barry, J.R.; Langer, R.; Vunjak-Novakovic, G. Chondrogenesis in a cell-polymer-bioreactor system. Exp. Cell Res. 1998, 240, 58–65, doi:10.1006/excr.1998.4010.
[15]
Freed, L.E.; Vunjak-Novakovic, G. Tissue Engineering Bioreactors. In Principles of Tissue Engineering, 2nd; Lanza, R.P., Langer, R., Vacanti, J.P., Eds.; Academic Press: San Diego, CA, USA, 2000; pp. 143–156. Chapter 13.
[16]
Peppas, N.A.; Langer, R. New challenges in biomaterials. Science 1994, 263, 1715–1720.
[17]
Kohn, J.; Langer, R. Polymerization reactions involving the side chains of α-l-amino acids. J. Am. Chem. Soc. 1987, 109, 817–820, doi:10.1021/ja00237a030.
[18]
Pachence, J.M.; Kohn, J. Biodegradable Polymers. In Principles of Tissue Engineering, 2nd; Lanza, R.P., Langer, R., Vacanti, J.P., Eds.; Academic Press: San Diego, CA, USA, 2000; pp. 263–277.
Drury, J.L.; Mooney, D.J. Hydrogels for tissue engineering: Scaffold design variables and applications. Biomaterials 2003, 24, 4337–4351, doi:10.1016/S0142-9612(03)00340-5.
[21]
Peppas, N.A.; Carr, D.A. Impact of absorption and transport on intelligent therapeutics and nano-scale delivery of protein therapeutic agents. Chem. Eng. Sci. 2009, 64, 4553–4565, doi:10.1016/j.ces.2009.04.050.
[22]
Baptista, P.M.; Orlando, G.; Mirmalek-Sani, S.H.; Siddiqui, M.; Atala, A.; Soker, S. Whole Organ Decellularization- a Tool for Bioscaffold Fabrication and Organ Bioengineering. In Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC ’09), Minneapolis, MN, USA, 3–6 September 2009; pp. 6526–6529.
Tissue Engineering and Cell Transplantation: US Markets for Skin Replacements and Substitutes; Report #A426; Medtech Insight: Bridgeport, PA, USA, 2010.
[25]
Guidance Document for the Conduct of Skin Absorption Studies. In OECD Environmental Health and Safety Publications, Series on Testing and Assessment, No. 28; Organisation for Economic Co-Operation and Development: Paris, France, 2004.
[26]
Panchagnula, R.; Stemmer, K.; Ritschel, W.A. Animal models for transdermal drug delivery. Methods Find. Exp. Clin. Pharmacol. 1997, 19, 335–341.
[27]
Kiowski, G.; Biedermann, T.; Widmer, D.S.; Civenni, G.; Burger, C.; Dummer, R.; Sommer, L.; Reichmann, E. Engineering melanoma progression in a humanized environment in vivo. J. Invest. Dermatol. 2011, 132, 144–153.
[28]
Commandeur, S.; Ho, S.H.; de Gruijl, F.R.; Willemze, R.; Tensen, C.P.; EI-Ghalbzouri, A. Functional characterization of cancer-associated fibroblasts of human cutaneous squamous cell carcinoma. Exp. Dermatol. 2011, 20, 737–742.
[29]
Tjabringa, G.; Bergers, M.; van Rens, D.; de Boer, R.; Lamme, E.; Schalkwijk, J. Development and validation of human psoriatic skin equivalents. Am. J. Pathol. 2008, 173, 815–823, doi:10.2353/ajpath.2008.080173.
[30]
MacNeil, S. Progress and opportunities for tissue-engineered skin. Nature 2007, 445, 874–880, doi:10.1038/nature05664.
[31]
Groen, D.; Poole, D.S.; Gooris, G.S.; Bouwstra, J.A. Is an orthorhombic lateral packing and a proper lamellar organization important for the skin barrier function? Biochim. Biophys. Acta 2011, 1808, 1529–1537, doi:10.1016/j.bbamem.2010.10.015.
[32]
Nowak, J.A.; Fuchs, E. Isolation and culture of epithelial stem cells. Methods Mol. Biol. 2009, 482, 215–232, doi:10.1007/978-1-59745-060-7_14.
[33]
Midwood, K.S.; Williams, L.V.; Schwarzbauer, J.E. Tissue repair and the dynamics of the extracellular matrix. Int. J. Biochem. Cell Biol. 2004, 36, 1031–1037, doi:10.1016/j.biocel.2003.12.003.
[34]
Herndon, D.N.; Barrow, R.E.; Rutan, R.L.; Rutan, T.C.; Desai, M.H.; Abston, S. A comparison of conservative versus early excision. Therapies in severely burned patients. Ann. Surg. 1989, 209, 547–553, doi:10.1097/00000658-198905000-00006.
Groeber, F.; Holeiter, M.; Hampel, M.; Hinderer, S.; Schenke-Layland, K. Skin tissue engineering- in vivo and in vitro applications. Adv. Drug Deliv. Rev. 2011, 63, 352–366, doi:10.1016/j.addr.2011.01.005.
[37]
O’Conner, N.E.; Mulliken, J.B.; Banks-Schlegel, S.; Kehinde, O.; Green, H. Grafting of burns with cultured epithelium prepared from autologous epidermal cells. Lancet 1981, 317, 75–78.
[38]
Purdue, G.F. Dermagraft-TC pivotal efficacy and safety study. J. Burn Care Rehabil. 1997, 18, S13–S14, doi:10.1097/00004630-199701001-00007.
[39]
Gentzkow, G.D.; Iwasaki, S.D.; Hershon, K.S.; Mengel, M.; Prendergast, J.J.; Ricotta, J.J.; Steed, D.P.; Lipkin, S. Use of dermagraft: A cultured human dermis to treat diabetic foot ulcers. Diabetes Care 1996, 19, 350–354.
[40]
Cuono, C.; Langdon, R.; McGuire, J. Use of cultured epidermal autografts and dermal allografts as skin replacement after burn injury. Lancet 1986, 327, 1123–1124, doi:10.1016/S0140-6736(86)91838-6.
[41]
Heimbach, D.; Luterman, A.; Burke, J.; Cram, A.; Herndon, D.; Hunt, J.; Jordan, M.; McManus, W.; Solem, L.; Warden, G.; Zawacki, B. Artificial dermis for major burns: A multi-center randomized clinical trial. Ann. Surg. 1988, 208, 313–320, doi:10.1097/00000658-198809000-00008.
[42]
Shevchenko, R.V.; James, S.L.; James, S.E. A review of tissue-engineered skin bioconstructs available for skin reconstruction. J. R. Soc. Interface 2010, 7, 229–258, doi:10.1098/rsif.2009.0403.
[43]
Maruguchi, T.; Maruguchi, Y.; Suzuki, S.; Matsuda, K.; Toda, K.; Isshiki, N. A new skin equivalent: Keratinocytes proliferated and differentiated on collagen sponge containing fibroblasts. Plast. Reconstr. Surg. 1994, 93, 537–544.
[44]
Eaglstein, W.H.; Iriondo, M.; Laszlo, K. A composite skin substitute (graftskin) for surgical wounds: A clinical experience. Dermatol. Surg. 1995, 21, 839–843, doi:10.1016/1076-0512(94)00290-8.
[45]
Sabolinski, M.L.; Alvarez, O.; Auletta, M.; Mulder, G.; Parenteau, N.L. Cultured skin as a “smart material” for healing wounds: Experience in venous ulcers. Biomaterials 1996, 17, 311–320, doi:10.1016/0142-9612(96)85569-4.
[46]
Bello, Y.M.; Falabella, A.F. The role of graftskin (apligraf) in difficult-to-heal venous leg ulcers. J. Wound Care 2002, 11, 182–183.
[47]
Boyce, S.T.; Kagen, R.J.; Greenhalgh, D.G.; Warner, P.; Yakuboff, K.P.; Palmieri, T.; Warden, G.D. Cultured skin substitutes reduce requirements for harvesting of skin autograft for closure of excised, full-thickness burns. J. Trauma 2006, 60, 821–829.
[48]
Ponec, M. Skin constructs for replacement of skin tissues for in vitro testing. Adv. Drug Deliv. Rev. 2002, 54, S19–S30, doi:10.1016/S0169-409X(02)00112-6.
[49]
Johsnon, E.W.; Meunier, S.F.; Roy, C.J.; Parenteau, N.L. Serial cultivation of normal human keratinocytes: A defined system for studying the regulation of growth and differentiation. In Vitro Cell. Dev. Biol. 1992, 28, 429–435, doi:10.1007/BF02634047.
[50]
Boehnke, K.; Mirancea, N.; Pavesio, A.; Fusenig, N.E.; Boukamp, P.; Stark, H.J. Effects of fibroblasts and microenvironment on epidermal regeneration and tissue function in long-term skin equivalents. Eur. J. Cell Biol. 2007, 86, 731–746, doi:10.1016/j.ejcb.2006.12.005.
[51]
Xie, Y.; Rizzi, S.C.; Dawson, R.; Lynam, E.; Richards, S.; Leavesley, D.I.; Upton, Z. Development of a three-dimensional human skin equivalent wound model for investigating novel wound healing therapies. Tissue Eng. Part C Method 2010, 16, 1111–1123, doi:10.1089/ten.tec.2009.0725.
[52]
Oliver, G.J.; Pemberton, M.A.; Rhodes, C. An in vitro model for identifying skin-corrosive chemicals. 1. Initial validation. Toxicol. in Vitro 1988, 2, 7–17, doi:10.1016/0887-2333(88)90031-8.
[53]
Lelievre, D.; Justine, P.; Christiaens, F.; Bonaventure, N.; Coutet, J.; Marrot, L.; Cotovio, J. The Episkin Phototoxicity Assay (EPA): Development of an in vitro tiered strategy using 17 reference chemicals to predict phototoxic potency. Toxicol. in Vitro 2007, 21, 977–995, doi:10.1016/j.tiv.2007.04.012.
[54]
Gabbanini, S.; Lucchi, E.; Carli, M.; Berlini, E.; Minghetti, A.; Valgimigli, L. In vitro evaluation of the permeation through reconstructed human epidermis of essential oils from cosmetic formulations. J. Pharm. Biomed. Anal. 2009, 50, 370–376, doi:10.1016/j.jpba.2009.05.018.
[55]
de Jager, M.; Groenink, W.; van der Spek, J.; Janmaat, C.; Gooris, G.; Ponec, M.; Bouwstra, J. Preparation and characterization of a stratum corneum substitute for in vitro precutaneuous penetration studies. Biochim. Biophys. Acta 1758, 636–644.
Vicanova, J.; Boelsma, E.; Mommaas, A.M.; Kempenaar, J.A.; Forslind, B.; Pallon, J.; Egelrud, T.; Koerten, H.K.; Ponec, M. Normalization of epidermal calcium distribution profile in reconstructed human epidermis is related to improvement of terminal differentiation and stratum corneum barrier formation. J. Invest. Dermatol. 1998, 111, 97–106.
[58]
US and International Acceptance of Alternative Methods, 1998–2011 Chronological List, published by NICEATM-ICCVAM. Available online: http://iccvam.niehs.nih.gov/about/accept.htm (accessed on 23 December 2011).
[59]
The Regulatory Acceptance for Skin Corrosion and Skin Irritation can be found at the Method Validation website of ECVAM. Available online: http://ecvam.jrc.it/ (accessed on 23 December 2011).
[60]
Stark, H.J.; Boehnke, K.; Mirancea, N.; Willhauck, M.J.; Pavesio, A.; Fuesnig, N.E.; Boukamp, P. Epidermal homeostasis in long-term scaffold-enforced skin equivalents. J. Investig. Dermatol. Symp. Proc. 2006, 11, 93–105, doi:10.1038/sj.jidsymp.5650015.
[61]
EI-Ghalbzouri, A.; Lamme, E.N.; van Blitterswijk, C.; Koopman, J.; Ponec, M. The use of PEGT/PBT as a dermal scaffold for skin tissue engineering. Biomaterials 2004, 25, 2987–2996, doi:10.1016/j.biomaterials.2003.09.098.
[62]
Thakoersing, V.S.; Ponec, M.; Bouwstra, J.A. Generating of human skin equivalents under submerged conditions- mimicking the in utero environment. Tissue Eng. Part A 2010, 16, 1433–1441, doi:10.1089/ten.tea.2009.0358.
[63]
Ponec, M.; Weerheim, A.; Kempenaar, J.; Mulder, A.; Gooris, G.S.; Bouwstra, J.; Mommaas, A.M. The formation of competent barrier lipids in reconstructed human epidermis requires the presence of vitamin C. J. Invest. Dermatol. 1997, 109, 348–355.
[64]
Thakoersing, V.S.; Gooris, G.S.; Mulder, A.; Rietveld, M.; EI-Ghalbzouri, A.; Bouwstra, J.A. Unraveling barrier properties of three different in-house human skin equivalents. Tissue Eng. Part C 2012, 18, 1–11.
[65]
Andreadis, S.T.; Hamoen, K.E.; Yarmush, M.L.; Morgan, J.R. Keratinocyte growth factor induces hyperproliferation and delays differentiation in a skin equivalent model system. FASEB J. 2001, 15, 898–906, doi:10.1096/fj.00-0324com.
[66]
Schmook, F.P.; Meingassner, J.G.; Billich, A. Comparison of human skin or epidermis models with human and animal skin in in-vitro percutaneous absorption. Int. J. Pharm. 2001, 215, 51–56, doi:10.1016/S0378-5173(00)00665-7.
[67]
Roy, S.D.; Fujiki, J.; Fleitman, J.S. Permeabilities of alkyl p-amino-benzoates through living skin equivalent and cadaver skin. J. Pharm. Sci. 1993, 82, 1266–1268, doi:10.1002/jps.2600821217.
[68]
Batheja, P.; Song, Y.; Wertz, P.; Michniak-Kohn, B. Effects of growth conditions on the barrier properties of a human skin equivalent. Pharm. Res. 2009, 26, 1689–1700, doi:10.1007/s11095-009-9879-1.
[69]
Wilkins, L.M.; Watson, S.R.; Prosky, S.J.; Meunier, S.F.; Parenteau, N.L. Development of a bilayered living skin construct for clinical applications. Biotechnol. Bioeng. 1994, 43, 747–756, doi:10.1002/bit.260430809.
